Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (76)	11/7/2000 11:39:36 AM
From: keokalani'nui	Read Replies (1) \| Respond to of 1022

Avanir fills out Xenerex's SAB: The new Scientific Advisory Board members are: Donald E. Mosier, Ph.D., M.D., a Professor/Member of the Department of Immunology at The Scripps Research Institute in La Jolla, California, will be the Chairman of Xenerex's Scientific Advisory Board. He is a member of multiple advisory panels and on the editorial review board of five scientific journals in the immunology field. Dr. Mosier led the group that discovered that human lymphocytes were able to survive and function when implanted into mice with the severe combined immunodeficiency (SCID) mutation and were then capable of generating fully human antibodies. This discovery led to the technology now used by scientists at Xenerex to generate human monoclonal antibodies. K. Frank Austen, M.D. is a Theodore Bevier Bayles Professor of Medicine at Harvard Medical School and the director of Inflammation and Allergic Diseases Research in the Division of Rheumatology, Immunology and Allergy at Brigham and Women's Hospital in Boston, Massachusetts. Dr. Austen is an internationally known immunologist who has published over 500 medical journal articles and edited thirteen medical texts. His academic career began at Harvard Medical School in 1961 and he has received numerous awards and honors, served on many committees and editorial boards and is a distinguished lecturer. J. Donald Capra, M.D. is the president of Oklahoma Medical Research Foundation and the Department Head of the Molecular Immunogenetics Research Program as well as an adjunct professor in the Department of Microbiology and Immunology at the University of Oklahoma Health Services Center. Dr. Capra's research focuses on the immune system at the molecular level. He is particularly interested in the genetic origin of human antibodies and their structure, and also in the role of a specialized white blood cell, the T cell, in human immune system responses. He has published over 350 medical journal articles related to these areas. Michel Andre' Duchosal, M.D. is affiliated with the Division of Hematology of the Department of Medicine at the University Hospital in Lausanne, Switzerland and has published over 30 articles on immunology in medical journals. Dr. Duchosal's research focuses on the human immune system with emphasis on its in vivo functionality. He is especially interested in mechanisms contributing to the perpetuation of the immune response. Dr. Duchosal has been the recipient of several awards including in 1997 the Ellerman Award by the Swiss Society of Hematology.